Infinity Pharmaceuticals Inc. (NASDAQ:INFI) has announced positive outcomes for the Phase II trials of a study called Dynamo.
The trial was a monotherapy study seeking to identify the safety and efficiency of a treatment known as duvelisib which is an experimental oral drug for patients suffering from refractory indolent non-Hodgkin lymphoma (iNHL). The pharmaceutical company reported that the drug achieved its primary endpoint which was the overall rate of response. The overall response rate for duvelisib was 46% which was recorded as partial responses from 129 patients diagnosed with iNHL. Most of the test subjects in the trial experienced side effects which were clinically reversible and manageable.
Infinity’s president and CEOAdelene Perkins stated that even though the drug met its primary endpoints, the researchers had hoped that the treatment would offer greater benefits to patients whose iNHL is in the advanced stages. The CEO further added that the firm will consult the Food and Drug Administration to determine which will advise Infinity on the next steps as far as duvelisib is concerned.
Infinity is also still holding talks with AbbVie Inc (NYSE:ABBV) where they are discussing plans regarding their collaborative efforts. The two companies have decided to postpone the Phase 1b/2 study which was sponsored by AbbVie and involves a combination of venetoclax and duvelisib. The decision to put the study on hold was influenced by the ongoing business discussions as they wait for a resolution. Infinity is also carrying out corporate restructuring efforts that will lead to the closure of its discovery research organization. These efforts will affect 46 employees of the company.
Perkins stated that the restructuring efforts are necessary for the company so that it can maintain its resources. It is also a strategy for the firm to allow for exploration of more options for duvelisib as well as advancement of the firm’s second clinical program known as IPI-549. The CEO stated that the restructuring efforts were a difficult decision for the company, and he expressed appreciation to those who will be affected by the changes.
